Smith et al. [49]
|
|
Docosahaxaenacid (DHA) (260 oder 520 mg/d)
|
|
Adults
|
n=28 mild to moderate MMD, non-responsive to medication/psychotherapy. 8-week open-label pilot trial of low-dose DHA, (260 mg or 520 mg/day), no placebo control
|
54% of patients had a ≥50% reduction on the HAM-D. 45% were in remission. Significant reduction in the HAMD score for middle insomnia no significance in reduction in excessive daytime somnolence on the total Epworth Sleepiness Scale (ESS). No significant adverse reactions to DHA. Improvement of CGI. Adjunctive benefits in patients with mild to moderate depression
|
lack of a placebo small sample size serum and RBC fatty acid status not examined smoking was not controlled (modifies the metabolism of omega 3)
|
Sahraian et al. [61]
|
Suicidality
|
Vit C (1000 mg/d)
|
|
Adults
|
8-week randomized double-blind placebo-controlled clinical trial. adult patients with MMD n=78, n=21 treatment (vitamin c) group, n=22 placebo group 35 drop outs treatment group received Citalopram+Vit C; placebo group received Citalopram+placebo
|
Depression symptoms decreased in both groups, no statistically significant difference between the 2 groups
|
small sample size short duration fixed dose of Vit C no control of dietary intake of Vit C
|
Stokes et al. [38]
|
Chron. Liver disease
|
Vit D (20,000 UI/Week)
|
|
Adults
|
cross-sectional analysis, n=111 patients with chronic liver disease. n=34 depression. n=77 no depression
|
results indicate that Vit D substitution might significantly improve depressive symptoms in CLD (in particular in women with low baseline Vit D)
|
intervention was not an RCT, small sample size
|
Payne et al. [36]
|
|
Antioxidants
|
Vit C
|
Adults
|
case-control study, longitudinal clinical examination, n=278, n=144 participants with depression, n=134 participants without depression
|
Participants with depression: significantly lower intake of fruits, vegetables, vitamin C, and ß-cryptoxanthin than participants without depression
|
Sample size. No confirmation of causal relationship between depression and nutrition -> antidepressants may have an effect on appetite an diet. Severely depressed persons were excluded. Self-report of dietary intake=not objective. generalization only to older adults (outicipants older than 60) from Europe with non-severe depression receiving psychiatric treatment
|
von Känel et al. 20105
|
|
|
|
Adults
|
n=380 depressed participants (n=27 drop out). Depression measured using: HADS-D, BDI2 and Brief Symptom Inventory. Serum levels of 25-hydroxyVit D3 (25-OH D) were measured
|
Vit D deficiency is associated with cognitive/affective depressive symptoms, especially anhedonia symptoms
|
observational design/retrospectively collected data. confounding factors cannot be excluded No measurement of physical activity, sun exposure, nutrition depressive symptoms not measured by a clinical interview. method of Vit measurement changed through the study
|
Gowda et al. [40]
|
|
Vit D
|
|
Adults
|
meta-analysis of randomized controlled trials, n=4923, Vit D supplementation to reduce depression/depressive symptoms MEDLINE, EMBASE, psych INFO, CINAHL plus, and Cochrane library
|
no significant effect was seen, no significant reduction in depression
|
most studies focused on participants with mild depressive symptoms and sufficient serum Vit D
|
Mousa et al. [41]
|
|
Vit D (Calciol 4000 IU/d)
|
|
Adults (18–60; obese; Vit D ≤50 nmol/L)
|
randomized, placebo-controlled cross-sectional analyses, n=63 (48 completed trial) (n=33 Vit D group) (n=32 placebo)
|
no association between increased risk of depression and Vit D deficiency in persons without clinically significant depression
|
small sample size short duration (16-week intervention) BDI scores in normal range. Healthy young individuals. No measurement of factors influencing depressing symptoms
|
Marsh et al. [42]
|
|
Vit D (5000 IU/d)
|
|
Adults (18–70 years)
|
double blind placebo-controlled trial n=230 (randomized n=33; n=16 Vit D, n=17 placebo)
|
both treatments (Vit D/placebo) did not improve reduction in mood elevation or anxiety symptoms
|
small sample size low Vit D levels in the supplementation group at conclusion
|
Kiecolt-Glaser et al. [50]
|
Depression
|
Omega-3 (2,5 g/d, 2085 mg Eicosapentacid+348 mg Docosahaxaenacid)
|
|
Adults (21–29)
|
Placebo-controlled, double-blind 12-week RCT. n=68 (medical students, 6 visits ->alternating between lower stress an higher stress (non-exam and major exam)
|
Participants that received n-3 showed a decrease in lipopolysaccharide (LPS) stimulated interleukin 6 (IL-6) productions and a reduction in anxiety symptoms, without a change in depressive symptoms. n-3 supplementation can reduce inflammation and anxiety in young healthy adults. reduction in anxiety is associated with n-3 supplementation. n-3 may have potential anxiolytic benefits (healthy individuals without an anxiety diagnosis)
|
Not shown that n-3 supplemented participants would show smaller exam-related increments in inflammation and distress among compared to controls. absence of systematic stress-related changes in control group. possible side effects
|
Kjærgaard et al. [43]
|
|
Vit D3 (40 000 IU/week)
|
|
Adults (30–75); 25 (OH)D Level<55 nmol/L,>70 nmol/L
|
nested case–control study and randomized clinical trial. n=357 (n=243 case group (splited in treatment and placebo)/n=114 control group) 3 groups ->participants with low 25(OH)D levels were randomized to treatment group (40 000 IU Vit D3 per week for 6 months or placebo. Participants with high 25(OH)D levels ->nested controls
|
participants with low Vit D levels were significantly more depressed (at baseline). No effect of Vit D supplementation was found on depressive symptoms ->low levels of Vit D may be the results instead the cause of depressive symptoms
|
short duration to investigate depression . participants were informed about if they had high or low Vit D levels ->may biased their self-report of depressive symptoms. individuals with severe depressive symptoms were excluded from the intervention ->participants had no or mild depressive symptoms. possible side effects of supplementation
|
Jovanova et al. [12]
|
|
|
|
Adults (55+)
|
population-based cohort designed study, embedded in the Rotterdam study; n=3251
|
Low serum Vit D levels were cross-sectionally associated with more depressive symptom, but not with a change of depressive symptoms
|
unmeasured confounding factors no account for parathyroid hormone a(PTH) reverse causality between Vit D and Depression
|
Nguyen et al. [63]
|
|
Retinol
|
Retinla equivalent
|
Adults (65+)
|
cross-sectional study (based on “Shika Study” Measurements: interviews, self-administered questionnaires and comprehensive health examination) investigation between vitamin intake and depressive symptoms (n=1634)
|
except for retinol and Vit D, the consumption of all vitamins, was lower among depressed participants. no associations between the 15 vitamins in depressed male or underweight participants. relationship between Vit Deficiencies and depressive symptoms in female and overweight elderly participants
|
cross-sectional design does not provide evidence for causality. self-reported dietary assessment methods to measure vitamin intake ->subjective. some confounding factors (physical activity, economic income, history of drug use, diseases, history of vitamin supplements etc could not be excluded
|
Sepehrmanesh et al. [44]
|
Oxidative stress
|
Vit D (50 kIU/week)
|
|
Adults (18–65)
|
A Randomized, double blind, placebo-controlled Clinical Trial; n=40 with MDD ->1 group (n=20) received 50 kIU Vit D/week the other group (n=20) received placebo for 8 weeks. fasting blood samples were taken at baseline and after intervention Measurements: BDI and glucose homeostasis variables, lipid profiles, hs-CRP, and biomarkers of oxidative stress
|
trend towards a greater decrease in the BDI was observed in the Vit D group than in the control group Vit D supplementation of individuals with MDD ->showed beneficial effects on BDI, indicators of glucose homeostasis, and oxidative stress
|
Short duration. all participants had Vit D deficiency - no examination of individuals without Vit D deficiency
|
Rolf et al. [45]
|
Multiple sclerosis
|
Vitamin (14.000 IU/d)
|
|
Adults; multiple sclerosis
|
randomized pilot study n=40 relapsing remitting (RR)MS patients received Vit D3 supplementation (n=20) or placebo (n=20) during 48 weeks
|
no significantly different reductions between treatment and controls no reductions in pro- and anti-inflammatory cytokine balances, secreted by stimulated leukocytes and CD8+T cells were found in the Vit D3 compared to the controls. no evidence for a reduction of depressive symptoms or related biomarkers
|
|
Masoumi et al. [52]
|
|
Omega-3 (1 g/d)
|
|
Female (45–65 years)
|
triple-blind randomized controlled trial n=60 women with post-menopausal depression Group 1: 20 mg citalopram & placebo. Group 2: 20 mg citalopram 1 g omega-3
|
Trend of decreasing depression scores in intervention group (2) Sign. difference in depression scores between the groups
|
Small sample size
|
Penckofer et al. [39]
|
Anxiety
|
Vit D (25-hydroxyVit D) (50,000 IU/week
|
|
Female 18+; DM II
|
open-label, proof-of-concept study to assess the effect of Vit D2 supplementation on depression, anxiety, and mental health status. single-group, pretest-posttest design. n=82 medically stable Type 2 Diabetes Mellitus patients. A capsule of 50,000 IU of Vit D2 (ergocalciferol) was administered once a week for 6 months
|
significant decrease in depression and anxiety improvement in mental health status
|
No need to have significant depressive symptoms to participate no randomization short duration no control group
|
Yalamanchili & Gallagher [46]
|
|
Vit D (25 OHD) (400–4800 IU/d)
|
Calcium (1000–1400 mg/Tag)
|
Female 57–90 years
|
1-year, randomized, double-blind, multidose, Placebo-controlled study. n=274 elderly women with Vit D insufficiency
|
different doses of Vit D3 did not influence the depression score in Vit D insufficient older white and black women
|
Study not designed for depression. No data on socio-economic status – confounding factor
|
Singh et al. [64]
|
Stress
|
Thiamin
|
Riboflavin (Vitamin B2)
|
Female, pregnant
|
n=108 pregnant Latina teenager. Stress, depression and dietary intake was measured
|
social support was associated with a higher intake of thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, vitamin C, vitamin E, iron, and zinc
|
Sample size, recall bias
|
Khajehnasiri et al. [53]
|
stress
|
Omega-3 (2×1000 mg/d)
|
Vit C (2×250 mg/d)
|
Male (21–52 shift -workers)
|
randomized, double-blind, placebo-controlled trial, n=136 men Measures: BDI & MDA (malondialdehyd) TAC (total antioxidant capacity) concentrations. n=33 received omega-3 fatty acid soft gel (1000 mg twice daily) with vitamin C (250 mg twice daily) n=31 received omega-3 fatty acid supplements and vitamin C placebo. n=30 received omega-3 fatty acid supplement placebo and Vit C. n=32 received omega-3 fatty acid supplement placebo and Vit C placebo
|
BDI score was reduced Significantly in all 4 groups. The greatest decrease was in the omega-3-fatty-acid alone supplement group. MDA level decreased significantly in groups with omega-3 fatty acids or vitamin C supplementation alone. omega-3 fatty acids alone and not in combination with vitamin C had an higher impact on depression and reduced MDA levels
|
Short duration, Self-report bias of alcohol and drug use (Iran) because of cultural issues
|
Frandsen et al. [47]
|
|
Vit D (70 µg/d)
|
|
Nurses
|
randomized, single-centre, double-blind, placebo-controlled trial, n=34. Participants received a daily dose (during 3 months) of 70 μg Vit D or placebo. first outcome: the sum of the self-reported questionnaire Structured Interview Guide for the HAMD, Seasonal Affective Disorders (SIGH-SAD). The secondary outcome: WHO-5 of the healthcare professionals during the winter period
|
The sums of the SIGH–SAD at 12 weeks were not significantly different between the groups
|
exclusion criterion High PTH. drop-outs had lower 25(OH)D calculated sample size not reached
|
Khajehnasiri et al. [54]
|
|
Omega-3 (180 mg Eicosapentenacid+120 mg Docosahaxaenacid) 2×/d
|
Vit C (250 mg 2×/d)
|
Shift workers Iran, Petrolindustrie; (21–52)
|
Randomized, double blind, placebo-controlled and parallel-group clinical trial. n=136. Four groups of omega 3 and/or Vit C supplementation and/or placebo
|
Sign. reduction in all groups. Supplementation of omega 3 and Vit C is associated with a reduction of depressive scores. O3 supp showed a better effect and high sensitivity C-reactive protein
|
|
Parletta et al. [60]
|
|
Fishoil (2 Cap/d)
|
Mediteranian diet
|
|
Randomized controlled trial, n=152. Group 1: food hampers and MedDiet cooking workshops for 3 months and fish oil supplements for 6 months, Group 2: attend social groups fortnightly for 3 months
|
Higher MedDiet score, consumed more vegetables, fruit, nuts, legumes, and vegetable diversity, less unhealthy snacks and red meat/chicken. Group1 had greater reduction in depression and improved mental health at 3 months.
|
single blinded. Self-reported, high dropout rate
|
Sarris et al. [65]
|
|
Folatic Acid, B6, B12
|
Omega-3
|
|
Review of adjunctive nutraceuticals for depression
|
Folic acid significant as adjunctive treatment in combination with fluoxetine (not significant with escitalopram or other tested antidepressants). Vit B12 significant as adjunctive treatment in combination with TCA/imipraimine or SSRI/fluoxetine. Vit B6 and 12 combined with folic acid not significant. EPA/DHA combined with any antidepressant or citalopram showed significant results, but not significant in combination with sertaline. EPA vs DHA: EPA shows more decrease in depressive symptoms than DHA. Ethyl-EPA: reduction of depressive symptoms in 3 trials, no sign. results in 1 double blind RCT
|
|
Messamore et al. [55]
|
Bipolar disorder
|
PUFA
|
Eicosapentenacid
|
|
Review
|
Findings show: n-3 PUFA insufficiency is associated with pathophysiology and pathoetiology of mood Dysregulation. recommended: implementation of routine screening for and treatment of n-3-PUFA deficiency
|
|
Mocking et al. [56]
|
|
PUFA
|
Omega-3
|
|
Review. Randomized placebo-controlled trials. Effects of omega-3 PUFA supplementation on depression.PubMED/EMBASE
|
overall beneficial effect of omega-3 PUFAs on depression in particular higher doses of EPA and in patients taking antidepressants. Supplementation is most beneficial
|
|
Sarris et al. [57]
|
Bipolar disorder
|
Omega-3
|
N-acetyl cysteine
|
|
Review
|
positive results for adjunctive omega-3 for MDD and Bipolar Depression: (mainly EPA dominant formulations). N-acetylcysteine has shown effectiveness (in 1 RCT) in reducing depression in bipolar depression. Vit D showing beneficial effects in reducing depression.
|
|
Trebatickáa et al. 2017
|
Cardiovascular disease
|
Omega-3
|
|
|
Review
|
changes in metabolism were induced changing dietary ratio of omega-6 to omega-3 fatty acids ; increased pro-inflammatory mediators/modulations of different signaling pathways pathophysiological response related to both, cardiovascular diseases and depressive disorders.
|
|
Du et al. [58]
|
PTSD
|
PUFA
|
Cholesterin
|
|
Review. Nutrients: omega 3 fatty acids, antioxidants (vitamin C and zinc), members of the vitamin B family (Vitamin B12 , folic acid), magnesium and how they can protect against oxidative damage to mitochondria and lipids in the neuronal circuits associated with cognitive and affective behaviors
|
improving neurocognitive function, and therapeutic benefits for depression and suicidal behaviors. Regular consumption could be helpful to prevent mood disorders and suicidal behaviors in vulnerable individuals significantly support the therapeutic effect of antidepressants
|
|
Parker et al. 2016
|
|
Vit D (25-hydroxyVit D)
|
|
|
Review: empirical papers published in recent years were identified
|
association between Vit D insufficiency and depression, and for Vit D supplementation and augmentation in those with clinical depression who are Vit D deficient
|
more randomized controlled longitudinal trials needed to clarify the role of Vit D in the pathogenesis of depression and its treatment
|
Stefanowski et al. [48]
|
|
Vit D3
|
|
|
Review: searching the Medline and PubMed
|
depressed individuals are at higher risk of Vit D3 deficiency factors related to lifestyle (food, not active, have low physical activity, spend more time indoors) predispose to the emergence of Vit D3 deficiency. Vit D3 supplementation in patients with depression may have antidepressant effect. Continuous supplementation may reduce the risk of recurrence
|
|
Mulcahy et al. [37]
|
Schizophrenia
|
Vit D
|
Adults
|
|
Psychiatric illnesses often lead to an intake of medications that can inhibit the synthesis and absorption of Vit D. Recent literature supports that Vit D has implications in the CNS. No consistent results in human studies. Hard to define a cause and effect relationship
|
Risk of adding a supplement with questionable efficiency into a medication treatment. risk of adverse drug reactions and potential psychiatric exacerbation. Self-administration errors
|
|
Rakofsky & Dunlop [34]
|
|
|
|
|
Review literature search for randomized, controlled clinical trials using nutritional supplements in the treatment of Bipolar Depression (PubMed and Ovid MEDLINE)
|
Inconsistent results for nutritional supplements (O3FAs, vitamin C, NAC, inositol or citicholine), no evidence for folic acid, choline, and O3FA-cytidine
|
|